A clinical trial to study the efficacy of two Siddha drugs in patients with kidney stones.

RCT of two Siddha drugs in the management of Urolithiasis (kalladaippu)-Phase II

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/08/015491

Enrollment

Registered

2018-08-28

Start date

Unknown

Completion date

Unknown

Last updated

2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Urolithiasis Health Condition 2: N20-N23- Urolithiasis Health Condition 3: N20-N23- Urolithiasis

Interventions

Intervention1: Nandukkal parpam: Nandukkal parpam - 400mg is administered daily,twice a day for 30 days in One arm(30 patients) Intervention2: Nandukkal parpam and Neermulli kudineer: Nandukkal parpam

Eligibility

Inclusion criteria

Inclusion criteria: 1.Presence of any three following signs and symptoms; a)Intermittent dull colicky pain(groin to loin) b)Hematuria c)Frequent micturition d)Burning micturition. 2.Evidence of calculus in X-Ray(KUB region) and Ultrasonogram (KUB)region. 3)Patients with calculi of size 3mm to 10mm

Exclusion criteria

Exclusion criteria: 1.Stag horn calculi 2.H/o.DM,HT,PT,CVD 3.Severe UTI 4.Pregnant and lactating women 5.Hydronephrosis 6.Pyelonephrosis 7.Cystitis

Design outcomes

Primary

Measure	Time frame
Absence of calculus or atleast 25% (significant) reduction in number and size of calculi and reduction in the presence of pus cells,epithelial cells, RBCs and calcium oxalate crystals in urine at 31st day of trialTimepoint: 30 days	—

Secondary

Measure	Time frame
Assessing the safety of trial drugsTimepoint: 30 days	—

Countries

India

Contacts

Public ContactDr A Faridha

Siddha Regional Research Institute, Puducherry.

rksiddha@hotmail.com0413-2245072

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026